Hypothalamic bile acid-TGR5 signaling protects from obesity.


Journal

Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170

Informations de publication

Date de publication:
06 07 2021
Historique:
received: 23 10 2020
revised: 30 03 2021
accepted: 14 04 2021
pubmed: 23 4 2021
medline: 31 3 2022
entrez: 22 4 2021
Statut: ppublish

Résumé

Bile acids (BAs) improve metabolism and exert anti-obesity effects through the activation of the Takeda G protein-coupled receptor 5 (TGR5) in peripheral tissues. TGR5 is also found in the brain hypothalamus, but whether hypothalamic BA signaling is implicated in body weight control and obesity pathophysiology remains unknown. Here we show that hypothalamic BA content is reduced in diet-induced obese mice. Central administration of BAs or a specific TGR5 agonist in these animals decreases body weight and fat mass by activating the sympathetic nervous system, thereby promoting negative energy balance. Conversely, genetic downregulation of hypothalamic TGR5 expression in the mediobasal hypothalamus favors the development of obesity and worsens established obesity by blunting sympathetic activity. Lastly, hypothalamic TGR5 signaling is required for the anti-obesity action of dietary BA supplementation. Together, these findings identify hypothalamic TGR5 signaling as a key mediator of a top-down neural mechanism that counteracts diet-induced obesity.

Identifiants

pubmed: 33887197
pii: S1550-4131(21)00175-3
doi: 10.1016/j.cmet.2021.04.009
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
Gpbar1 protein, mouse 0
Receptors, G-Protein-Coupled 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1483-1492.e10

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Ashley Castellanos-Jankiewicz (A)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Omar Guzmán-Quevedo (O)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France; Laboratory of Neuronutrition and Metabolic Disorders, Instituto Tecnológico Superior de Tacámbaro, 61650 Tacámbaro, Michoacán, Mexico; Pós-Graduação em Neuropsiquiatria e Ciências do Comportamento, Universidade Federal de Pernambuco, 50732-970 Recife, Pernambuco, Brazil.

Valérie S Fénelon (VS)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Philippe Zizzari (P)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Carmelo Quarta (C)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Luigi Bellocchio (L)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Anne Tailleux (A)

University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59019 Lille, France.

Julie Charton (J)

University of Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, EGID, F-59000 Lille, France.

Daniela Fernandois (D)

University of Lille, INSERM, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S1172, EGID, F-59000, Lille, France.

Marcus Henricsson (M)

The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.

Catherine Piveteau (C)

University of Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France.

Vincent Simon (V)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Camille Allard (C)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Sandrine Quemener (S)

University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59019 Lille, France.

Valentine Guinot (V)

University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59019 Lille, France.

Nathalie Hennuyer (N)

University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59019 Lille, France.

Alessia Perino (A)

Institute of Bioengineering, Faculty of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

Alexia Duveau (A)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Marlène Maitre (M)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Thierry Leste-Lasserre (T)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Samantha Clark (S)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Nathalie Dupuy (N)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Astrid Cannich (A)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Delphine Gonzales (D)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Benoit Deprez (B)

University of Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, EGID, F-59000 Lille, France.

Gilles Mithieux (G)

INSERM U1213 Nutrition, Diabetes and the Brain, University of Lyon 1 Faculté de Médecine Lyon-Est, 69372 Lyon, France.

David Dombrowicz (D)

University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59019 Lille, France.

Fredrik Bäckhed (F)

The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health Sciences, University of Copenhagen, 2200 N Copenhagen, Denmark; Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Physiology, Gothenburg, Sweden.

Vincent Prevot (V)

University of Lille, INSERM, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S1172, EGID, F-59000, Lille, France.

Giovanni Marsicano (G)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France.

Bart Staels (B)

University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59019 Lille, France.

Kristina Schoonjans (K)

Institute of Bioengineering, Faculty of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

Daniela Cota (D)

University of Bordeaux, INSERM, Neurocentre Magendie, U1215, F-3300 Bordeaux, France. Electronic address: daniela.cota@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH